JAZZ Jazz Pharmaceuticals plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: JAZZ

Price (delayed)

$240.4

Market cap

$15.43B

P/E Ratio

66.04

Dividend/share

N/A

EPS

$3.64

Enterprise value

$19.02B

?
Relative Growth: Rel. Growth: 50
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: 47
Relative Profitability: Rel. Profitability: 76

Jazz Pharmaceuticals plc is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for ...

Highlights
Jazz Pharmaceuticals's quick ratio has increased by 19% YoY and by 7% from the previous quarter
The gross profit has grown by 14% YoY and by 3.3% from the previous quarter
The company's EPS has surged by 161% YoY but it has shrunk by 76% QoQ
Jazz Pharmaceuticals's net income has surged by 156% YoY but it has shrunk by 78% QoQ
The company's debt rose by 28% QoQ and by 4% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.jazzpharma.com
Peers: NVS TEVA PRGO

Key stats

What are the main financial stats of JAZZ

JAZZ stock price

How has the Jazz Pharmaceuticals stock price performed over time
Intraday
-3.16%
1 week
5.75%
1 month
10.91%
1 year
75.85%
YTD
41.41%
QTD
3.84%

Financial performance

How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$4.72B
Gross profit
$4.2B
Operating income
$425.94M
Net income
$205.95M
Gross margin
89.1%
Net margin
4.4%
The operating income has surged by 186% year-on-year but it has dropped by 53% since the previous quarter
JAZZ's operating margin has soared by 176% year-on-year but it has dropped by 54% since the previous quarter
Jazz Pharmaceuticals's net income has surged by 156% YoY but it has shrunk by 78% QoQ
The company's net margin has surged by 149% YoY but it has shrunk by 78% QoQ

Price vs fundamentals

How does JAZZ's price correlate with its fundamentals

Growth

What is Jazz Pharmaceuticals's growth rate over time

Valuation

What is Jazz Pharmaceuticals stock price valuation
JAZZ P/E details
P/E
66.04
P/B
3.72
P/S
3.3
EV/EBIT
44.5
EV/EBITDA
16.6
EV/Sales
4.03
The company's EPS has surged by 161% YoY but it has shrunk by 76% QoQ
The price to book (P/B) is 60% higher than the 5-year quarterly average of 2.4 and 32% higher than the last 4 quarters average of 2.9
Jazz Pharmaceuticals's equity has decreased by 13% from the previous quarter but it has increased by 6% YoY
The price to sales (P/S) is 48% more than the 5-year quarterly average of 2.3 and 17% more than the last 4 quarters average of 2.9
The revenue has grown by 13% YoY and by 2.5% from the previous quarter

Efficiency

How efficient is Jazz Pharmaceuticals business performance
JAZZ's ROIC has soared by 190% YoY but it has shrunk by 53% QoQ
The company's return on sales has surged by 175% YoY but it has shrunk by 53% QoQ
The company's return on assets has surged by 156% YoY but it has shrunk by 78% QoQ
The return on equity has surged by 149% year-on-year but it has dropped by 79% since the previous quarter

Dividends

What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JAZZ.

Financial health

How did Jazz Pharmaceuticals financials performed over time
The total assets is 54% greater than the total liabilities
JAZZ's total liabilities is up by 24% since the previous quarter and by 6% year-on-year
Jazz Pharmaceuticals's quick ratio has increased by 19% YoY and by 7% from the previous quarter
The company's debt is 34% higher than its equity
Jazz Pharmaceuticals's debt to equity has increased by 46% QoQ but it has decreased by 2.2% YoY
The company's debt rose by 28% QoQ and by 4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.